ArticleCellular and molecular gastroenterology and hepatology2020
Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse.
Article in Cellular and molecular gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Regulated necrosis at the crossroads of liver inflammation and cancer development.Nature reviews. Gastroenterology & hepatology · 2026Review
- Pyroptosis Plays a Key Role Through Macrophages in Primary Biliary Cholangitis of Mice.BioMed research international · 2026Article
- LGALS3 marks a pro-inflammatory, efferocytosis-low hepatic macrophage state and promotes hepatic stellate cell activation through the candidate receptor ANXA2 in liver cirrhosis.Frontiers in immunology · 2026Article
- PROM2 exacerbates CCl4-Induced liver fibrosis via NLRP3 inflammasome activation and hepatocyte pyroptosis.Cellular and molecular life sciences : CMLS · 2025Article
- Review: Progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma.Cell communication and signaling : CCS · 2025Review
- The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data.Frontiers in immunology · 2025Article
- Iridoids in gardenia fruit: key components in liver disease therapy.Frontiers in nutrition · 2025Review
- Bile acids attenuate hepatic inflammation during ischemia/reperfusion injury.JHEP reports : innovation in hepatology · 2024Article
- NLRP3 Inflammasome in Acute and Chronic Liver Diseases.International journal of molecular sciences · 2024Review
- Uncovering a Novel Functional Interaction Between Adult Hepatic Progenitor Cells, Inflammation and EGFR Signaling During Bile Acids-Induced Injury.International journal of biological sciences · 2024Article
- Melatonin attenuates cholestatic liver injury via inhibition of the inflammatory response.Molecular and cellular biochemistry · 2023Article
- Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in theJHEP reports : innovation in hepatology · 2023Article
- Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat.BMC genomics · 2023Article
- Interleukin-1ß Attenuates Expression of Augmenter of Liver Regeneration (ALR) by Regulating HNF4α Independent of c-Jun.International journal of molecular sciences · 2023Article
- Effect of Percutaneous Biliary Drainage on Enzyme Activity of Serum Matrix Metalloproteinase-9 in Patients with Malignant Hilar Obstructive Hyperbilirubinemia.Medicina (Kaunas, Lithuania) · 2023Article
- Hepatic TNFRSF12A promotes bile acid-induced hepatocyte pyroptosis through NFκB/Caspase-1/GSDMD signaling in cholestasis.Cell death discovery · 2023Article
- AIM2 sensors mediate immunity toProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Pannexin1 channels in the liver: an open enemy.Frontiers in cell and developmental biology · 2023Review
- Inflammasome and pyroptosis in autoimmune liver diseases.Frontiers in immunology · 2023Review
- Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis.Science translational medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND &
aimsInflammation plays an important role in the pathogenesis of cholestatic liver injury, but it is unclear whether the inflammasome is involved and is the objective of this study.
methodsGene expression was analyzed in the livers of patients with primary biliary cholangitis (n = 15) and primary sclerosing cholangitis (n = 15). Bile duct ligation (BDL) or sham operation was performed in wild-type (WT) and Caspase-1
resultsCaspase-1, NLRP1, NLRP3 and IL-1β were significantly increased in the livers of cholestatic patients when compared to healthy control subjects (n = 9). Significantly higher levels of plasma IL-1β (826 vs 345 pg/ml), ALT (674 vs 482 U/L) and ALP (900 vs 622 U/L) were seen in WT BDL mice compared to Casp1
conclusionsThe inflammasome exacerbates cholestatic liver injury, but bile acids do not directly activate the inflammasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.